Тoday, Solopharm is ranked 5th in terms of sales among all Russian pharmaceutical manufacturers and is the fastest growing company among the top 10 largest Russian manufacturers. According to analysts, in industries such as medicines, dietary supplements and medical devices, growth was +51% in rubles for the first 8 months of 2021.
The dynamic development of Solopharm makes it possible to purchase the company's products in more than 13 countries and 700 cities around the world. They are used in various therapy areas: ophthalmology, otolaryngology, pulmonology, rheumatology, neurology, traumatology, therapy, cosmetology.
Solopharm has its own R&D department and laboratories, which allow it to carry out full-cycle pharmaceutical development. Currently, the company's portfolio includes more than 130 marketing authorizations and the same number of drugs are currently at various stages of development. At the beginning of 2022, it is planned to expand production capacities and complete the construction of a new plant for the production of solid dosage forms. Investments in the new plant are amounted to more than 3.5 billion rubles.
General information about the new plant:
• The plant area - 11 559 m2
• Building volume - 83 801 m2
• Building area - 3 952 m2
• High-tech jobs - 185
